Search clinical trials for: Rubella

Total 141 results

Liaoning Chengda Biotechnology CO., LTD

Recruiting

Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)

Japanese Encephalitis | Measles | Rubella | Mumps

China
GlaxoSmithKline
Kwame Nkrumah University of Science and Technology; European & Developing Countries... and other collaborators

Recruiting

A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants

Salmonella Infections

Ghana
Shanghai Municipal Center for Disease Control and...
China National Biotec Group Company Limited

Not yet recruiting

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines

Measles | Rubella | Mumps | Varicella | SARS-CoV-2 Infection

China
University of Zurich
Merck Sharp & Dohme LLC

Recruiting

Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster Vaccination (MIPS)

Measles | Rubella | Mumps

Switzerland
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (MEQ00064)

Healthy Volunteers | Meningococcal Immunisation

South Africa, India
International Centre for Diarrhoeal Disease Research...
Centers for Disease Control and Prevention

Not yet recruiting

Co-administration Study of OCV, TCV and MR

Measles | Rubella | Cholera | Typhoid
Laure Pittet, MD-PhD

Recruiting

Non-specific Effects of a Modified Measles Vaccination Schedule to Prevent Allergy and Unrelated Infection in Children (NEMAU)

Infections | Respiratory Tract Infections | Allergy | Eczema

Switzerland
GlaxoSmithKline

Recruiting

A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age

Measles; Mumps; Rubella; Chickenpox

United States
University of Oxford
Malaria Research and Training Center, Bamako, Mali

Recruiting

Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines

Malaria

Mali, United Kingdom
The Immunobiological Technology Institute (Bio-Manguinhos)...

Not yet recruiting

Immunity Duration Study Eight Years After Vaccination of Children 12 to 23 Months With the Triple Viral Vaccine (Measles, Mumps and Rubella)

Measles Vaccine
GlaxoSmithKline

Recruiting

A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants

Diarrhoea

Belgium, Kenya
Klara M. Pósfay Barbe
University Hospital, Geneva

Recruiting

Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients (MMRinOLT)

Measles

Switzerland
GlaxoSmithKline
IQVIA, USA

Active, not recruiting

A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

Chickenpox

Taiwan, Poland, United States, Estonia, Puerto Rico, Mexico
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa (MET55)

Healthy Volunteers (Meningococcal Infection)

India, South Africa
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Healthy Volunteers (Meningococcal Infection)

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers (MET41)

Healthy Volunteers (Meningococcal Infection)

Puerto Rico, United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

Healthy Volunteers (Meningococcal Infection)

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants

Pertussis Immunisation | Diphtheria Immunisation | Tetanus Immunisation | Pneumococcal Immunisation | Hepatitis B Immunisation | Haemophilus Influenzae Type b Immunisation | Polio Immunisation | Measles Immunisation | Rubella Immunisation | Varicella Immunisation | Mumps Immunisation

United States, Canada, Honduras, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico (MET33)

Healthy Volunteers (Meningococcal Infection)

Mexico, Russian Federation
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Prospective Trial of Vaccine Responses in Childhood Cancer Survivors

Childhood Cancer | Multiple Diseases

United States
Shanghai Institute Of Biological Products

Completed

Clinical Trial of Measles, Mumps and Rubella Combined Vaccine, Live

Vaccine | Immunotoxicity

China
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026) (PNEU-PED-EU-2)

Pneumococcal Infections

Denmark, Finland, Italy, Norway, Sweden
Micron Biomedical, Inc
Medical Research Council; Centers for Disease Control and Prevention

Completed

Measles and Rubella Vaccine Microneedle Patch Phase 1-2 Age De-escalation Trial

Healthy | Measles | Rubella | Vaccination

Gambia
Stanford University

Completed

Ontogeny of Measles Immunity in Infants

Measles

United States
Zhejiang Provincial Center for Disease Control...

Active, not recruiting

The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine

Measles | Rubella | Mumps | Human Papilloma Virus Infection Type 16 | Human Papilloma Virus Infection Type 18

China
Sanofi Pasteur, a Sanofi Company

Completed

A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers

Meningitis | Meningococcal Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers

Dengue | Dengue Hemorrhagic Fever

Mexico
Sanofi Pasteur, a Sanofi Company

Completed

Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers

Yellow Fever | Dengue | Dengue Hemorrhagic Fever

Peru, Colombia
Zagazig University

Completed

Triple Antigen vs Monoantigen Immunotherapy for Warts

Triple Intralesional Immunotherapy Combination in Multiple Recalcitrant Warts

Egypt
Rigshospitalet, Denmark

Completed

MMR at 6 Months Trial

Meales-mumps-rubella Vaccine

Denmark
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV Drugs

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs

HIV Infections | Hepatitis B | Measles | Pneumococcal Infections | Pertussis

United States, Puerto Rico
Themis Bioscience GmbH

Completed

Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine (MV-CHIK-202)

Chikungunya Virus Infection

Austria, Germany
National Institute of Allergy and Infectious Diseases...
Merck Sharp & Dohme LLC

Completed

A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group

HIV Infections | Measles

United States, Puerto Rico
Merck Sharp & Dohme LLC

Completed

Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)

Measles | Mumps | Varicella

France, Germany
Sri Edupuganti, MD MPH
Merck Sharp & Dohme LLC

Completed

Measles, Mumps, and Rubella (MMR) Immunity in College Students

Measles | Rubella | Mumps

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.

Malaria | Malaria Vaccines

Ghana
University of Oxford
University College, London; Public Health England

Completed

Baby Vaccine Study (Sched3)

Infectious Diseases

United Kingdom
Sinovac (Dalian) Vaccine Technology Co., Ltd.

Completed

Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine

Mumps

China
Asan Medical Center

Completed

Antithrombin III and Post-liver Transplantation Acute Kidney Injury

Liver Transplantation and Antithrombin

Korea, Republic of
B.P. Koirala Institute of Health Sciences
Nepal Health Research Council

Completed

A Comparative Study to Assess Efficacy of Intralesional MMR Vaccine and Intralesional Vitamin D3 in Treatment of Warts (MMR)

Verruca Viral

Nepal
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

Measles; Mumps; Rubella | Measles-Mumps-Rubella Vaccine

United States, Finland, Taiwan, Estonia, Puerto Rico
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

Measles | Rubella | Mumps | Measles-Mumps-Rubella Vaccine

Finland, Thailand, United States, Spain, Czechia, Puerto Rico, Malaysia
Centers for Disease Control and Prevention
International Centre for Diarrhoeal Disease Research, Bangladesh; Ministry...

Completed

Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age

Measles | Rubella | Rubella Syndrome, Congenital

Bangladesh
Kasr El Aini Hospital

Suspended

Measles Vaccine in HCW (MV-COVID19)

Covid19

Egypt
PATH
Syneos Health; Research Institute for Tropical Medicine; DF/Net Research, Inc.

Completed

Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine

Encephalitis, Japanese | Measles | Rubella | Mumps

Philippines
The Immunobiological Technology Institute (Bio-Manguinhos)...
Oswaldo Cruz Institute

Completed

Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella (BIOMR)

Measles | Rubella

Brazil
Assiut University

Completed

Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts

Plantar Wart | Common Wart

Egypt
GlaxoSmithKline

Completed

Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines

Tetanus | Diphtheria | Acellular Pertussis

United States
GlaxoSmithKline

Completed

Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age

Measles | Rubella | Mumps | Measles-Mumps-Rubella Vaccine

United States, Puerto Rico

Search clinical trials for: Rubella

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations